Vericel Corporation
VCEL
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B
$40.19
▼ -0.69%
P/E
85.91
Mkt Cap
$2.1B
52-Wk Range
$28.95–$49.32
52-Week Range
$28.95 - $49.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 21.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary autologous cell therapy technology with established manufacturing capabilities
- FDA-approved products with established market presence and reimbursement pathways
- Orphan drug designation and humanitarian use device status providing regulatory advantages
- Specialized expertise in cellular therapy commercialization and clinical application
Bear Case
2 risks
- Average volatility.
- Growth premium of 3.4x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Growth
Stable outlook
Expanding MACI adoption in orthopedic surgery and sports medicine markets
Value
Growth premium of 3.4x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Momentum
Strong
+12.4% over 3m
Quality
Excellent
High-growth business (23% revenue growth, 75% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying VCEL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
JUL 30, 2026
Reported EPS of $0.04 vs -$0.03 consensus (+238.2% surprise). Revenue of $77.5M vs $72.7M expected (+6.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+238.2%
Revenue trend · last 8Q
—
+16%
+3%
+20%
+17%
+23%
+30%
+22%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$57.9M
$75.4M
$52.6M
$63.2M
$67.5M
$92.9M
$68.4M
$77.5M
Margins · last 8Q
Gross
72.8%
Operating
0.6%
Profit
2.9%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Jul 31, 2026
vs Industry
How VCEL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related